Literature DB >> 11888721

Pain management and prescription monitoring.

David E Joranson1, Grant M Carrow, Karen M Ryan, Linda Schaefer, Aaron M Gilson, Patricia Good, John Eadie, Susan Peine, June L Dahl.   

Abstract

Preventing diversion and abuse of prescription controlled substances while ensuring their availability for legitimate medical use is an important public health goal in the United States. In one approach to preventing and identifying drug diversion, 17 states have implemented prescription monitoring programs (PMPs) to monitor the prescribing of certain controlled substances. While PMPs are not intended to interfere with legitimate prescribing, some in the pain management community feel that they negatively affect prescribing for pain management. This article describes a collaborative project initiated by the Pain & Policy Studies Group that brought together regulatory and pain management representatives twice in 1998 to share perspectives and reconcile differing views on the effects of PMPs. The ultimate goals of this project are to provide accurate information to healthcare clinicians about PMPs, better define the balance between preventing drug diversion and providing pain management, and promote continued dialog and cooperation among the groups.

Entities:  

Mesh:

Year:  2002        PMID: 11888721     DOI: 10.1016/s0885-3924(01)00410-9

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  11 in total

1.  Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options.

Authors:  Meredith Y Smith; George Woody
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

2.  Changes in illicit opioid use across Canada.

Authors:  Benedikt Fischer; Jürgen Rehm; Jayadeep Patra; Michelle Firestone Cruz
Journal:  CMAJ       Date:  2006-11-21       Impact factor: 8.262

3.  The effects of North Carolina's prescription drug monitoring program on the prescribing behaviors of the state's providers.

Authors:  Chris Ringwalt; Mariana Garrettson; Apostolos Alexandridis
Journal:  J Prim Prev       Date:  2015-04

4.  Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes.

Authors:  Aaron M Gilson; Scott M Fishman; Barth L Wilsey; Carlos Casamalhuapa; Hassan Baxi
Journal:  J Pain       Date:  2011-11-23       Impact factor: 5.820

5.  Mechanisms of prescription drug diversion among impaired physicians.

Authors:  Simone Marie Cummings; Lisa Merlo; Linda Cottler
Journal:  J Addict Dis       Date:  2011 Jul-Sep

6.  Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011.

Authors:  Corey S Davis; Matthew Pierce; Nabarun Dasgupta
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

Review 7.  Overview of four prescription monitoring/review programs in Canada.

Authors:  Andrea D Furlan; Peter MacDougall; Denise Pellerin; Karen Shaw; Doug Spitzig; Galt Wilson; Janet Wright
Journal:  Pain Res Manag       Date:  2014 Mar-Apr       Impact factor: 3.037

8.  ORIGINS OF THE OPIOID CRISIS AND ITS ENDURING IMPACTS.

Authors:  Abby Alpert; William N Evans; Ethan M J Lieber; David Powell
Journal:  Q J Econ       Date:  2021-11-13

Review 9.  Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention.

Authors:  V K Podichetty; D J Mazanec; R S Biscup
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

10.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.